IGF2BP2/IMP-2 Antibody [H6A9]

Catalog No.: F2804

    Home Primary Antibodies IGF2BP2/IMP-2 Antibody [H6A9]

    For research use only.

    Application: Reactivity:

    Usage Information

    Dilution
    1:2000 - 1:5000
    1:200
    1:100 - 1:250
    Application
    WB, IHC, IF
    Reactivity
    Mouse, Rat, Human
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    66 kDa 75 kDa, 70 kDa, 15 kDa, 66 kDa, 60 kDa,62 kDa
    *Why do the predicted and actual molecular weights differ?
    The following reasons may explain differences between the predicted and actual protein molecular weight.

    Datasheet & SDS

    Biological Description

    Specificity
    IGF2BP2/IMP-2 Antibody [H6A9] detects endogenous levels of total IGF2BP2/IMP-2 protein.
    Clone
    H6A9
    Synonym(s)
    IMP2; VICKZ2; IGF2BP2; Insulin-like growth factor 2 mRNA-binding protein 2; IGF2 mRNA-binding protein 2; IMP-2; Hepatocellular carcinoma autoantigen p62; IGF-II mRNA-binding protein 2; VICKZ family member 2
    Background
    IGF2BP2, also known as IMP-2, is an RNA-binding protein belonging to the IGF2 mRNA-binding protein family, characterized by two N-terminal RNA recognition motifs (RRMs) and four C-terminal K homology (KH) domains, which are essential for RNA binding, stability, and localization. These domains mediate the formation of stable ribonucleoprotein complexes essential for mRNA transport, storage, and translational regulation, preferentially binding to N6-methyladenosine (m6A)-modified mRNAs. IGF2BP2 'cages' target transcripts by recruiting them to cytoplasmic protein-RNA assemblies (mRNPs), protecting them from degradation and regulating their spatial and temporal translation; it specifically binds to the 5′-UTR of insulin-like growth factor 2 (IGF2) mRNAs and enhances the stability of oncogenic transcripts like MYC by binding to the coding region instability determinant (CRD), a process enhanced by m6A modifications. IGF2BP2 is implicated in cancer progression and metabolic disorders through its regulation of target mRNAs involved in proliferation and metabolism.
    References
    • https://pubmed.ncbi.nlm.nih.gov/38405706/
    • https://pubmed.ncbi.nlm.nih.gov/29736175/

    Tech Support

    Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3
    If you have any other enquiries, please leave a message.

    * Indicates a Required Field

    Please enter your name.
    Please enter your email. Please enter a valid email address.
    Please write something to us.